231 related articles for article (PubMed ID: 20492655)
1. Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study).
Bardini G; Giorda CB; Pontiroli AE; Le Grazie C; Rotella CM
Cardiovasc Diabetol; 2010 May; 9():20. PubMed ID: 20492655
[TBL] [Abstract][Full Text] [Related]
2. Ezetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in coronary heart disease patients.
Averna M; Zaninelli A; Le Grazie C; Gensini GF
J Clin Lipidol; 2010; 4(4):272-8. PubMed ID: 21122660
[TBL] [Abstract][Full Text] [Related]
3. Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes.
Rotella CM; Zaninelli A; Le Grazie C; Hanson ME; Gensini GF
Lipids Health Dis; 2010 Jul; 9():80. PubMed ID: 20663203
[TBL] [Abstract][Full Text] [Related]
4. Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease.
Barrios V; Amabile N; Paganelli F; Chen JW; Allen C; Johnson-Levonas AO; Massaad R; Vandormael K
Int J Clin Pract; 2005 Dec; 59(12):1377-86. PubMed ID: 16351668
[TBL] [Abstract][Full Text] [Related]
5. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia.
Bays HE; Ose L; Fraser N; Tribble DL; Quinto K; Reyes R; Johnson-Levonas AO; Sapre A; Donahue SR;
Clin Ther; 2004 Nov; 26(11):1758-73. PubMed ID: 15639688
[TBL] [Abstract][Full Text] [Related]
6. Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study.
Reckless JP; Henry P; Pomykaj T; Lim ST; Massaad R; Vandormael K; Johnson-Levonas AO; Lis K; Brudi P; Allen C
Int J Clin Pract; 2008 Apr; 62(4):539-54. PubMed ID: 18266852
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial.
Goldberg AC; Sapre A; Liu J; Capece R; Mitchel YB;
Mayo Clin Proc; 2004 May; 79(5):620-9. PubMed ID: 15132403
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
Roeters van Lennep HW; Liem AH; Dunselman PH; Dallinga-Thie GM; Zwinderman AH; Jukema JW
Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326
[TBL] [Abstract][Full Text] [Related]
9. Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease.
Farnier M; Volpe M; Massaad R; Davies MJ; Allen C
Int J Cardiol; 2005 Jul; 102(2):327-32. PubMed ID: 15982505
[TBL] [Abstract][Full Text] [Related]
10. Begin with the real-world patients of non-goal-achieved hypercholesterolemia in taiwan through the ezetimibe/simvastatin tablet - The BRAVO Study.
Huang JC; Lee TY; Liou MJ; Lin CM; Pei D; Chen ZC; Liu RT; Kwok CF
Curr Med Res Opin; 2011 Aug; 27(8):1645-51. PubMed ID: 21699369
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.
Avellone G; Di Garbo V; Guarnotta V; Scaglione R; Parrinello G; Purpura L; Torres D; Campisi D
Int Angiol; 2010 Dec; 29(6):514-24. PubMed ID: 21173733
[TBL] [Abstract][Full Text] [Related]
12. Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis.
Ambegaonkar BM; Tipping D; Polis AB; Tomassini JE; Tershakovec AM
Atherosclerosis; 2014 Dec; 237(2):829-37. PubMed ID: 25463129
[TBL] [Abstract][Full Text] [Related]
13. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
McCormack T; Harvey P; Gaunt R; Allgar V; Chipperfield R; Robinson P;
Int J Clin Pract; 2010 Jul; 64(8):1052-61. PubMed ID: 20487050
[TBL] [Abstract][Full Text] [Related]
14. LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD.
McKenney J; Ballantyne CM; Feldman TA; Brady WE; Shah A; Davies MJ; Palmisano J; Mitchel YB
MedGenMed; 2005 Jul; 7(3):3. PubMed ID: 16369229
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study.
Ballantyne CM; Hoogeveen RC; Raya JL; Cain VA; Palmer MK; Karlson BW;
Atherosclerosis; 2014 Jan; 232(1):86-93. PubMed ID: 24401221
[TBL] [Abstract][Full Text] [Related]
16. Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia.
Farnier M; Guyton JR; Jensen E; Polis AB; Johnson-Levonas AO; Brudi P
Atherosclerosis; 2013 Aug; 229(2):415-22. PubMed ID: 23880197
[TBL] [Abstract][Full Text] [Related]
17. Effects of ezetimibe on plasma lipoproteins in severely hypercholesterolemic patients treated with regular LDL-apheresis and statins.
Geiss HC; Otto C; Hund-Wissner E; Parhofer KG
Atherosclerosis; 2005 May; 180(1):107-12. PubMed ID: 15823282
[TBL] [Abstract][Full Text] [Related]
18. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.
Catapano AL; Davidson MH; Ballantyne CM; Brady WE; Gazzara RA; Tomassini JE; Tershakovec AM
Curr Med Res Opin; 2006 Oct; 22(10):2041-53. PubMed ID: 17022864
[TBL] [Abstract][Full Text] [Related]
19. Ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 mg in high cardiovascular risk patients with primary hypercholesterolemia: a randomized, double-blind, active-controlled, multicenter study.
Hing Ling PK; Civeira F; Dan AG; Hanson ME; Massaad R; De Tilleghem Cle B; Milardo C; Triscari J
Lipids Health Dis; 2012 Jan; 11():18. PubMed ID: 22293030
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of ezetimibe/simvastatin 10/40 mg compared to doubling the dose of low-, medium- and high-potency statin monotherapy in patients with a recent coronary event.
Brudi P; Reckless JP; Henry DP; Pomykaj T; Lim ST; Massaad R; Vandormael K; Johnson-Levonas AO
Cardiology; 2009; 113(2):89-97. PubMed ID: 19018143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
